Investigating how Wnt/Ca2+ signaling affects triple-negative breast cancer spread and treatment resistance
Official title: Functional role of Wnt/Ca2+ signaling in triple-negative breast cancer metastasis and chemoresistance
Funded at Baylor College of Medicine · NIH-11054431 · Data updated 2026-11-12
This study is looking at how calcium signals in cells might help triple-negative breast cancer spread and resist treatment, using special mice to learn more about it, with the hope of finding better ways to treat patients like you.
Quick facts
| Grant type | Career grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Baylor College of Medicine NIH-funded |
| Lab location | 1 site (Houston, United States) |
| Project start | March 7, 2025 |
| Project end | February 28, 2027 |
| Funding year | 2025 |
| Award (this year) | $125,834 |
| NIH project number | 1K99CA290088-01A1 |
| Project ID | NIH-11054431 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates for this research are individuals diagnosed with triple-negative breast cancer, particularly those experiencing metastasis or treatment resistance.
✕Less likely to help
Patients with non-triple-negative breast cancer types or those who have not developed metastasis may not benefit from this research.
What this research studies
This research focuses on understanding the role of calcium signaling in the spread and treatment resistance of triple-negative breast cancer (TNBC). Researchers will create a specialized mouse model that can measure calcium levels in real-time, allowing them to explore how Wnt signaling pathways influence cancer cell behavior. By identifying the mechanisms behind metastasis and drug resistance, the study aims to uncover potential new therapeutic targets for TNBC. Patients may benefit from insights that could lead to more effective treatments.
Why it matters
Potential benefit: If successful, this research could lead to new treatment strategies that improve outcomes for patients with triple-negative breast cancer.
How similar studies have gone: Previous research has shown promising results in targeting calcium signaling pathways in cancer, suggesting that this approach may yield significant insights.
Where this research is happening
-
Baylor College of Medicine
Houston, United States Active
Researchers
- Principal investigator: Si, Hongjiang — Baylor College of Medicine
- Study coordinator: Si, Hongjiang
Related research
Other NIH-funded projects on the same topics.
-
Stable, ultra-tight peptides to block EphB4 and stop TNBC spread
A new peptide-based approach aims to block a cancer molecule called EphB4 to prevent metastasis in triple-negative breast cancer, especially in African American women.
-
Understanding how high triglycerides may fuel certain breast cancers
High triglycerides may help triple negative breast cancer grow and spread, and this study looks at how that could happen in patients and models.
-
Stopping triple-negative breast cancer spread by targeting EYA3 and PP2A
Researchers are exploring whether blocking the EYA3/PP2A pathway can prevent triple-negative breast cancer from spreading and help the immune system fight the tumor.
-
How low PHGDH changes sugar metabolism to help triple‑negative breast cancer spread
This project looks at how low levels of the enzyme PHGDH change sialic acid sugar metabolism in ways that help triple‑negative breast cancer cells spread.
-
Stable, ultra‑high affinity peptides that block EphB4 to stop triple‑negative breast cancer from spreading
Designer peptides that latch onto the EphB4 protein are being developed to try to stop triple‑negative breast cancer from spreading, with attention to the higher risk seen in African American women.
-
How high triglycerides may help triple negative breast cancer grow and spread
Researchers are looking at whether high blood triglyceride levels make triple negative breast cancer grow and spread faster, which could point to ways to help women with TNBC.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.